http://www.biotheranostics.com/privacy-policy.html WebHologic announced a $230 million deal in which it will acquire Biotheranostics, a private company that provides molecular diagnostic tests for breast and metastatic cancers. Through the purchase, Hologic aims to enhance its current work in the field of oncology with more personalized treatment and better outcomes for women.

Hologic Looks to Expand Profile in Breast Cancer Testing With ...

WebJan 5, 2024 · Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing … WebCancerTYPE ID ® is performed and billed separately by NeoGenomics’ contracted reference laboratory, Biotheranostics, Inc., an independent CLIA-licensed and CAP … red gowns 2015

Visit the Hologic.com Customer Sign-in Page

WebJan 6, 2024 · M edical technology company Hologic Inc. has announced the acquisition of privately-held Biotheranostics Inc. in a deal worth $230 million. Shares of Hologic, … WebBiotheranostics was acquired by Hologic in February 2024, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in … WebFeb 22, 2024 · MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million.Biotheranostics develops and markets two highly differentiated molecular … knott\u0027s berry farm owners